Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (NASDAQ:ALVO) held its 2026 Annual and Extraordinary General Meeting on June 3, 2026, in Luxembourg. All draft resolutions on the agenda were approved. Notarized minutes and detailed voting results will be made available on the company’s dedicated 2026 AGM web portal.
Alvotech (NASDAQ: ALVO) announced that Founder and Executive Chairman Robert Wessman and Chief Strategy Officer Dr. Balaji V. Prasad will speak at three investor events in June 2026.
They will join fireside chats at Jefferies Global Healthcare, Goldman Sachs Global Healthcare, and UBS Virtual Generics and Biosimilars Day, all with live and archived webcasts.
Alvotech (Nasdaq: ALVO) and Islandsbanki renewed and amended their market making agreement for ALVO shares on Nasdaq Iceland. Islandsbanki will place bid and ask quotes with an aggregate market value of at least ISK 8 million and a maximum spread of 2.5%. The daily net trading volume is capped at ISK 16 million. The amended, open-ended agreement was executed on May 29, 2026, and can be terminated by either party with 7 days’ notice.
Alvotech (NASDAQ: ALVO) reported completion of a routine FDA cGMP surveillance inspection at its Reykjavik, Iceland manufacturing facility, ending May 8, 2026, with issuance of a Form 483.
The company believes observations are addressable, remains on track to resubmit the relevant BLAs in Q2 2026, and continues to expect FDA approvals during 2026.
Alvotech (NASDAQ: ALVO) reported Q1 2026 revenue of $105.9m versus $132.8m year-ago and adjusted EBITDA $24.4m with gross margin 57%. Management said production slowdowns for facility improvements reduced near-term volumes. Post-period, Alvotech filed EMA applications for AVT16 and AVT80, started a pivotal AVT29 study for high-dose Eylea HD, and signed a U.S. manufacturing agreement with FUJIFILM Biotechnologies. 2026 guidance: revenues $650–700m and adjusted EBITDA $180–220m.
Alvotech (NASDAQ: ALVO) announced on April 30, 2026 that General Counsel Tanya Zharov has asked to step down after six years and will remain during a multi-month handover. The company named Lisa Graver taking over the CEO role and noted some executive relocations to Reykjavik.
The release says Zharov will assume responsibilities for chairman Róbert Wessman’s holding companies, Aztiq and Flóki, while supporting Alvotech during transition.
Alvotech (NASDAQ: ALVO) will release first quarter 2026 financial results on Wednesday, May 6, 2026 after U.S. market close. A webcast with live Q&A is scheduled for Thursday, May 7, 2026 at 08:00 EST (12:00 GMT).
Slides and presentation materials will be posted on the company's investor events page before the call. Registration links and investor/media contact emails are provided for access and inquiries.
Alvotech (NASDAQ: ALVO) filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission on March 30, 2026. The filing incorporates parts of the Alvotech Annual Report 2025 and is publicly available on the SEC website and Alvotech investor relations site.
For investor or media inquiries, Alvotech provided contact emails for media and investor relations on its investor site.
Alvotech (NASDAQ: ALVO) published its 2025 Annual Report on March 30, 2026. The report is available in the company's investor relations website and is attached to the announcement in PDF and iXBRL formats. Contact details for media and investors are provided for further inquiries.
Alvotech (NASDAQ: ALVO) reported Q4 2025 revenues of $173M (+13% YoY) and FY 2025 revenues of $593M (+21% YoY). Adjusted EBITDA was $69M in Q4 and $137M for FY 2025 (+27% YoY). Cash on Dec 31, 2025 was $172M. Multiple biosimilar approvals and commercial deals were announced; management reaffirmed 2026 guidance of $650–700M revenue and $180–220M adjusted EBITDA.
Company cited regulatory observations from an FDA inspection and plans to resubmit affected applications in Q2 2026 while expanding partnerships and acquisitions.